Design and antitumor activity of programmed cell death ligand 1 epitope peptide vaccine
10.11665/j.issn.1000-5048.2023022803
- VernacularTitle:细胞程序性死亡配体1表位肽疫苗的设计及抗肿瘤活性
- Author:
Shishuai SHAO
1
;
Shukang DUAN
;
Hong TIAN
;
Wenbing YAO
;
Xiangdong GAO
Author Information
1. 中国药科大学生命科学与技术学院 江苏省生物药物成药性研究重点实验室
- Publication Type:Journal Article
- Keywords:
tumor immunity;
immune checkpoint;
PD-L1;
epitope peptide vaccine
- From:
Journal of China Pharmaceutical University
2023;54(2):245-254
- CountryChina
- Language:Chinese
-
Abstract:
Several programmed cell death protein 1 (PD-1) or its ligand (PD-L1) immune checkpoint blocking antibodies are available for clinical treatment, but only some patients show clinical response, so an alternative strategy for tumor immunotherapy is needed.A therapeutic tumor vaccine targeting PD-L1 is a meaningful attempt.In this study, we designed an epitope peptide vaccine targeting PD-L1, and then screened the immunogenic PD-L1 epitope peptide based on the humanized immune system (HIS) mouse model and further investigated its anti-tumor activity.The results show that the designed and screened PD-L1-B1 epitope peptide vaccine not only successfully induced PD-L1-specific humoral and cellular immunity, but also exhibit anti-tumor activity.In addition, immunotherapy increased T-lymphocyte infiltration of tumors and reshaped the tumor immunosuppressive microenvironment.In conclusion, PD-L1-B1 epitope peptide vaccine exhibits potent anti-tumor activity and may be an effective alternative immunotherapeutic strategy for patients insensitive to PD-1/PD-L1 blockade.
